Supriya Lifescience Recommends Final Dividend of ₹1 Per Share
Supriya Lifescience's Board approved audited financial results for FY26. The company recommended a final dividend of ₹1 per share. Full-year revenue was ₹8,278.75 crore, with a profit after tax of ₹2,091.20 crore. The Board Meeting was held on May 27, 2026.
The recommendation of a final dividend and the reporting of positive financial results have a moderate impact on the company's stock and investor sentiment.
The company announced positive financial results and recommended a dividend, which are generally viewed favorably by investors.
Supriya Lifescience Limited announced the outcome of its Board Meeting held on May 27, 2026. The Board approved the Audited Financial Results for the quarter and year ended March 31, 2026. Additionally, the Board recommended a Final Dividend of ₹1.00 per equity share, representing 50% of the face value of ₹2 per share. This recommendation is subject to the approval of the shareholders at the upcoming Annual General Meeting (AGM). The details regarding the AGM will be communicated separately.
The Audited Financial Results for the period indicate a Revenue from Operations of ₹8,278.75 crore for the full year ended March 31, 2026, and ₹2,765.28 crore for the quarter ended March 31, 2026. The profit after tax for the year stood at ₹2,091.20 crore, with basic and diluted Earnings Per Share (EPS) at ₹25.98 for the full year.
The company also reported an incremental cost of ₹4.58 million towards employee benefits due to the implementation of the New Labour Codes. The Board Meeting commenced at 03:45 p.m. and concluded at 06:00 p.m.
What to do with a filing like this
Supriya Lifescience Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Supriya Lifescience Limited. Read the original for the full detail.